Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 25;14(1):41.
doi: 10.3390/pharmaceutics14010041.

Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment

Anita Bakrania  1   2   3 , Gang Zheng  3   4   5 , Mamatha Bhat  1   2   6   7
Affiliations
Review

Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment

Anita Bakrania et al. Pharmaceutics. .

Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and is associated with a dismal median survival of 2-9 months. The fundamental limitations and ineffectiveness of current HCC treatments have led to the development of a vast range of nanotechnologies with the goal of improving the safety and efficacy of treatment for HCC. Although remarkable success has been achieved in nanomedicine research, there are unique considerations such as molecular heterogeneity and concomitant liver dysfunction that complicate the translation of nanotheranostics in HCC. This review highlights the progress, challenges, and targeting opportunities in HCC nanomedicine based on the growing literature in recent years.

Keywords: gene therapy; hepatocellular carcinoma; liver cancer; nanomedicine; nanoparticle.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Illustration showing specific targets and ligands for HCC nanomedicine.
See this image and copyright information in PMC

References

    1. Wong C.-M., Tsang F.H.-C., Ng I.O.-L. Non-coding RNAs in hepatocellular carcinoma: Molecular functions and pathological implications. Nat. Rev. Gastroenterol. Hepatol. 2018;15:137. doi: 10.1038/nrgastro.2017.169. - DOI - PubMed
    1. Dhanasekaran R., Limaye A., Cabrera R. Hepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepatic Med. Evid. Res. 2012;4:19. - PMC - PubMed
    1. Nault J.-C., Datta S., Imbeaud S., Franconi A., Mallet M., Couchy G., Letouzé E., Pilati C., Verret B., Blanc J.-F. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat. Genet. 2015;47:1187–1193. doi: 10.1038/ng.3389. - DOI - PubMed
    1. Kew M.C. Aflatoxins as a cause of hepatocellular carcinoma. J. Gastrointest. Liver Dis. 2013;22:305–310. - PubMed
    1. Magnussen A., Parsi M.A. Aflatoxins, hepatocellular carcinoma and public health. World J. Gastroenterol. 2013;19:1508. doi: 10.3748/wjg.v19.i10.1508. - DOI - PMC - PubMed

LinkOut - more resources